Metellus
Gartenstrasse 10, Zürich, Zurich, 8002, Switzerland
Overview
Metellus is a private investment office based in Zurich and London, specialised in alternative investments (private equity, venture capital, real estate) and direct investments in technology and life sciences. Metellus takes an active ownership role to enhance value creation and is actively involved in the management of a diverse portfolio of investments in private equity and venture capital. Metellus is a member of SECA, the Swiss Private Equity & Corporate Finance Association.
- Total investments
- 3
- Lead investments
- 3
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Consulting
- Financial Services
- Venture Capital
Investment portfolio
- QuantalRF
Led · Series C · Apr 2022
QuantalRF is an RF semiconductor company focused on highly integrated CMOS-SOI front-end ICs, including power amplifiers, low-noise amplifiers and on-chip filters for 5G, Wi‑Fi and UWB. The company emphasizes ultra-compact solutions that aim to rival acoustic wave and GaAs performance while improving area, cost and power consumption. QuantalRF leverages a patented Quantal technology platform to enable rapid customization of filters and other RF front-end products. The firm notes a recent initial delivery of 5G filters to a long-term strategic partner, demonstrating early commercial traction. With more than 250 granted patents and applications, QuantalRF plans to expand its product portfolio and accelerate hiring to scale its technology and meet partner demand. The company is headquartered in Zürich, Switzerland, and has operations in the USA and Sweden. QuantalRF develops RF front-end integrated circuits including power amplifiers (PA), low-noise amplifiers (LNA) and on-chip filters for a range of wireless systems including Wi‑Fi 6/6e and 5G UHB. The company holds a portfolio of over 250 granted patents and applications and operates in Switzerland with activities in the USA and Sweden. Leadership includes CEO/CTO Dr. Ali Fard and Executive Chairman Antonio J. Viana. QuantalRF plans to accelerate commercialization of its patented RF front-end technologies, expand its engineering team and scale product development for 5G/UHB and Wi‑Fi 6/6e front-end IC components. The company completed a Series B equity financing of CHF17m (approximately $19m) to support those goals. The business was established based on inventions from co-founder Dr. Forrest J. Brown.
- Revolo Biotherapeutics
Led · Series B · Sep 2020
Immune Regulation is a US and UK based clinical‑stage biotechnology company pioneering technologies to regulate and reset the immune system. It is developing first‑in‑class immune‑resetting therapies, including IRL201805 and IRL201104, which have shown unique efficacy and safety in pre‑clinical and human studies. These therapies have short pharmacokinetic activity but are designed to shift the immune system from a pro‑inflammatory to a regulatory state to induce long‑term disease remission without broadly suppressing immunity. The company intends to use the new funds to accelerate development of drug product candidates for autoimmune and allergic diseases. The business is led by Group CEO Jonathan Rigby and is advancing multiple programs toward clinical objectives. Financially, the company completed a Series B equity financing and raised additional advance subscription funds as described in the financing announcement.
Team
No current team members are available.